Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Cell entry mechanisms of SARS-CoV-2
2020 Standout
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus
2009
Hepatitis C Virus Genotype 1a Growth and Induction of Autophagy
2007
Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes
2007
Effectiveness of a hospital-wide programme to improve compliance with hand hygiene
2000 Standout
Hepatocellular carcinoma
2003 Standout
Hepatitis C Virus and eliminating post-transfusion hepatitis
2000 StandoutNobel
Spatial and temporal analyses to investigate infectious disease transmission within healthcare settings
2014
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Hepatitis C Virus Infection
2001 Standout
Rising Incidence of Hepatocellular Carcinoma in the United States
1999 Standout
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
1998 Standout
The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice
2005
Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy
1997
Transmission of Hepatitis C Virus from a Patient to an Anesthesiology Assistant to Five Patients
2000
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies
2007 StandoutNobel
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
1999 Standout
Hepatitis C virus entry: Molecular biology and clinical implications
2006
Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo
2006 StandoutNobel
Cell entry of hepatitis C virus
2006
Virus glycosylation: role in virulence and immune interactions
2007
Epidemiology of hepatitis C
1997 Standout
Protective Immune Response to Hepatitis C Virus in Chimpanzees Rechallenged Following Clearance of Primary Infection
2001 StandoutNobel
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway
2008
Epidemiology of hepatitis C
1996
Cell culture–produced hepatitis C virus does not infect peripheral blood mononuclear cells
2008 StandoutNobel
Understanding the mechanisms and drivers of antimicrobial resistance
2015 Standout
Educational Levels of Hospital Nurses and Surgical Patient Mortality
2003 Standout
Hepatitis C Virus: Epidemiology, Transmission and Prevention
1998
Nosocomial transmission of hepatitis C virus
1997
Significance of the Anti‐E2 Response in Self‐Limited and Chronic Hepatitis C Virus Infections in Chimpanzees and in Humans
1999
Analysis of a Successful Immune Response against Hepatitis C Virus
1999 StandoutNobel
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
2009 StandoutNatureNobel
NATURAL RECOVERY FROM ACUTE HEPATITIS C VIRUS INFECTION BY AGAMMAGLOBULINEMIC TWIN CHILDREN
1997
The challenge of developing a vaccine against hepatitis C virus
2002
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
2007 StandoutNatureNobel
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
2010 StandoutNobel
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33
2006
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Hepatitis C Virus Entry
2007 StandoutNobel
Characterization of Antibodies Induced by Vaccination with Hepatitis C Virus Envelope Glycoproteins
2010 StandoutNobel
Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide
1996 StandoutNobel
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Antibody responses against B‐cell epitopes of the hypervariable region 1 of hepatitis C virus in self‐limiting and chronic human hepatitis C followed‐up using consensus peptides
2001
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Strategies and Prospects for Vaccination Against the Hepatitis C Viruses
2000 StandoutNobel
The Risk of Hepatitis C Virus Infection Among Blood Donors in Osaka, Japan
1998
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
1998 Standout
Antibodies Directed to Envelope Proteins of Hepatitis C Virus Outside of Hypervariable Region 1
1998
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
New therapeutic strategies for hepatitis C
2002 StandoutNobel
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees
2004 StandoutNobel
SARS-CoV-2 vaccines in development
2020 StandoutNature
Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production
2005 StandoutNobel
Replication of hepatitis C virus
2007 StandoutNobel
The B-cell receptor of a hepatitis C virus (HCV)–associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis
2001
Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions
2004
Induction of Broad CD4+and CD8+T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5
2008 StandoutNobel
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
2007
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes
2006
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus
2006
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia
2007 StandoutNobel
Human Monoclonal Antibodies That React With the E2 Glycoprotein of Hepatitis C Virus and Possess Neutralizing Activity *
2005
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein
2005
In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes
2003
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1
2005
Long-Term Follow-Up of Chimpanzees Inoculated with the First Infectious Clone for Hepatitis C Virus
1999 StandoutNobel
Viral Persistence, Antibody to E1 and E2, and Hypervariable Region 1 Sequence Stability in Hepatitis C Virus-Inoculated Chimpanzees
1999
The effect of health care working conditions on patient safety.
2003
V H 1-69 gene is preferentially used by hepatitis C virus–associated B cell lymphomas and by normal B cells responding to the E2 viral antigen
2001
Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step
2011
Neutralizing Antibody Response to Hepatitis C Virus
2011
Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries
2001
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures
2010 StandoutNobel
Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity
2009 StandoutNobel
Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients
2003 StandoutNobel
Future Therapies for Hepatitis C
2006
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
2015
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees
2000
Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2
2003
Compliance with Handwashing in a Teaching Hospital
1999
Works of Aster Beyene being referenced
Patients Infected with the Same Hepatitis C Virus Strain Display Different Kinetics of the Isolate-Specific Antibody Response
1997
Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward
1995
Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells
2004
Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity
2004
Hepatitis C Virus Envelope Glycoproteins and Potential for Vaccine Development
2002
Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells
2007
The Hypervariable Region 1 of the E2 Glycoprotein of Hepatitis C Virus Binds to Glycosaminoglycans, but This Binding Does Not Lead to Infection in a Pseudotype System
2004
Coexpression of Hepatitis C Virus E1 and E2 Chimeric Envelope Glycoproteins Displays Separable Ligand Sensitivity and Increases Pseudotype Infectious Titer
2004
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81
2000 StandoutNobel